SpringerLink
Log in

Potential nephroprotective effects of resveratrol in drug induced nephrotoxicity: a narrative review of safety and efficacy data

  • Review
  • Published:
Advances in Traditional Medicine Aims and scope Submit manuscript

Abstract

Drug induced nephrotoxicity commonly occurs in hospitalized patients and sometimes may complicate treatment outcome, especially in critically ill patients. No universal prophylactic agent is available yet to protect against drug related nephrotoxicity. Many modalities have been applied with different successes. Polyphenolic compounds such as resveratrol have been used both in-vitro and in vivo to prevent drug induced nephrotoxicity. Resveratrol have several antioxidant, antiplatelet and nitric oxide releasing properties in preclinical studies. In this review, we discuss recent studies that evaluated resveratrol protective effects, the mechanism of action and safety issues on drug induced nephrotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Al Dera HS (2016) Protective effect of resveratrol against aluminum chloride induced nephrotoxicity in rats. Saudi Med J 37(4):369. https://doi.org/10.15537/smj.2016.4.13611

    Article  PubMed  Google Scholar 

  • Albertoni G, Schor N (2015) Resveratrol plays important role in protective mechanisms in renal disease-mini-review. J Bras Nefrol 37(1):106–114

    PubMed  Google Scholar 

  • Alexander JW, Metze TJ, McIntosh MJ, Goodman HR, First MR, Munda R, Safdar S (2005) The influence of immunomodulatory diets on transplant success and complications. Transplantation 79(4):460–465

    CAS  PubMed  Google Scholar 

  • Amudha G, Josephine A, Varalakshmi P (2006) Role of lipoic acid in reducing the oxidative stress induced by cyclosporine A. Clin Chim Acta 372(1–2):134–139

    CAS  PubMed  Google Scholar 

  • Ansari KA, Vavia PR, Trotta F, Cavalli R (2011) Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS Pharmscitech 12(1):279–286

    CAS  PubMed  PubMed Central  Google Scholar 

  • Basavaraj S, Betageri GV (2014) Improved oral delivery of resveratrol using proliposomal formulation: investigation of various factors contributing to prolonged absorption of unmetabolized resveratrol. Exp Opin Drug Deliv 11(4):493–503

    CAS  Google Scholar 

  • Benesic A, Schwerdt G, Hennemeier I, Sauvant C, Mildenberger S, Gekle M (2014) The nephrotoxic Ifosfamide-metabolite chloroacetaldehyde interferes with renal extracellular matrix homeostasis. Cell Physiol Biochem 33(4):1106–1116

    CAS  PubMed  Google Scholar 

  • Berman AY, Motechin RA, Wiesenfeld MY, Holz MK (2017) The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol 1(1):35

    PubMed  PubMed Central  Google Scholar 

  • Bienholz A, Pang RM, Guberina H, Rauen U, Witzke O, Wilde B, Kribben A (2017) Resveratrol does not protect from ischemia-induced acute kidney injury in an in vivo rat model. Kidney Blood Press R 42(6):1090–1103

    CAS  Google Scholar 

  • Bonechi C, Martini S, Ciani L, Lamponi S, Rebmann H, Rossi C, Ristori S (2012) Using liposomes as carriers for polyphenolic compounds: the case of trans-resveratrol. PLoS ONE 7(8):e41438. https://doi.org/10.1371/journal.pone.0041438

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bradamante S, Barenghi L, Villa A (2004) Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 22(3):169–188

    CAS  PubMed  Google Scholar 

  • Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, Cseh J, Halmai R (2011) Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106(3):383–389

    PubMed  Google Scholar 

  • Burdmann EA, Andoh TF, Yu L, Bennett WM (2003) Cyclosporine nephrotoxicity. Semin Nephrol 23(5):465–476

    CAS  PubMed  Google Scholar 

  • Cai S, Yang Q, Bagby TR, Forrest ML (2011) Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev 63(10–11):901–908

    CAS  PubMed  PubMed Central  Google Scholar 

  • Carter LG, D'Orazio JA, Pearson KJ (2014) Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer 21(3):R209–R225. https://doi.org/10.1530/ERC-13-0171

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chander V, Chopra K (2005) Role of nitric oxide in resveratrol-induced renal protective effects of ischemic preconditioning. J Vasc Surg 42(6):1198–1205

    PubMed  Google Scholar 

  • Chander V, Chopra K (2006) Protective effect of nitric oxide pathway in resveratrol renal ischemia-reperfusion injury in rats. Arch Med Res 37(1):19–26

    CAS  PubMed  Google Scholar 

  • Chander V, Tirkey N, Chopra K (2005) Resveratrol, a polyphenolic phytoalexin protects against cyclosporine-induced nephrotoxicity through nitric oxide dependent mechanism. Toxicology 210(1):55–64

    CAS  PubMed  Google Scholar 

  • Chen JM, Bai JY, Yang KX (2018) Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway. IUBMB Life 70(6):491–500

    CAS  PubMed  Google Scholar 

  • Cid TP, Garcıa JC, Alvarez FC, De Arriba G (2003) Antioxidant nutrients protect against cyclosporine A nephrotoxicity. Toxicology 189(1–2):99–111

    Google Scholar 

  • Clément M-V, Hirpara JL, Chawdhury S-H, Pervaiz S (1998) Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92(3):996–1002

    PubMed  Google Scholar 

  • Colombo M, Cassano N, Bellia G, Vena G (2013) Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal. https://doi.org/10.1155/2013/805705

    Article  PubMed  PubMed Central  Google Scholar 

  • Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS (2004) Resveratrol-associated renal toxicity. Toxicol Sci 82(2):614–619

    CAS  PubMed  Google Scholar 

  • Darwish MA, Abo-Youssef AM, Khalaf MM, Abo-Saif AA, Saleh IG, Abdelghany TM (2018) Resveratrol influences platinum pharmacokinetics: a novel mechanism in protection against cisplatin-induced nephrotoxicity. Toxicol Lett 290:73–82

    CAS  PubMed  Google Scholar 

  • De Nicola L, Thomson SC, Wead LM, Brown MR, Gabbai FB (1993) Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 92(4):1859–1865

    PubMed  PubMed Central  Google Scholar 

  • Dera HA, Abushouk A (2015) Protective effect of resveratrol against aluminium chloride (AlCl3) induced testicular damage in rats entails inhibition of intrinsic apoptotic pathway. Sci Adv Mater 7(2):384–395

    Google Scholar 

  • Do Amaral CL, Francescato HDC, Coimbra TM, Costa RS, Darin JDAC, Antunes LMG, Bianchi MDLP (2008) Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol 82(6):363–370

    CAS  PubMed  Google Scholar 

  • Dubourg L, Michoudet C, Cochat P, Baverel G (2001) Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 12(8):1615–1623

    CAS  PubMed  Google Scholar 

  • El-Kashef D, El-Kenawi A, Suddek G, Salem H (2017) Allicin ameliorates kidney function and urinary bladder sensitivity in cyclosporine A-treated rats. Hum Exp Toxicol 36(7):681–691

    CAS  PubMed  Google Scholar 

  • El-Shitany NA, El-Haggar S, El-Desoky K (2008) Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol 46(7):2422–2428

    CAS  PubMed  Google Scholar 

  • El-Sheikh AA, Morsy MA, Al-Taher AY (2016) Protective mechanisms of resveratrol against methotrexate-induced renal damage may involve BCRP/ABCG2. Fundam Clin Pharmacol 30(5):406–418

    CAS  PubMed  Google Scholar 

  • Galletti P, Di Gennaro CI, Migliardi V, Indaco S, Della Ragione F, Manna C, Zappia V (2005) Diverse effects of natural antioxidants on cyclosporin cytotoxicity in rat renal tubular cells. Nephrol Dial Transpl 20(8):1551–1558

    CAS  Google Scholar 

  • Gambini J, Inglés M, Olaso G, Lopez-Grueso R, Bonet-Costa V, Gimeno-Mallench L, Vina J (2015) Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev 2015:837042. https://doi.org/10.1155/2015/837042

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gan Y, Tao S, Cao D, **e H, Zeng Q (2017) Protection of resveratrol on acute kidney injury in septic rats. Hum Exp Toxicol 36(10):1015–1022

    CAS  PubMed  Google Scholar 

  • Garvin S, Öllinger K, Dabrosin C (2006) Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231(1):113–122

    CAS  PubMed  Google Scholar 

  • Gehm BD, McAndrews JM, Chien P-Y, Jameson JL (1997) Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci 94(25):14138–14143

    CAS  PubMed  Google Scholar 

  • Gokce EH, Korkmaz E, Dellera E, Sandri G, Bonferoni MC, Ozer O (2012) Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int J Nanomed 7:1841. https://doi.org/10.2147/IJN.S29710

    Article  CAS  Google Scholar 

  • Goldhahn K, Schmetterer K, Steiner G, Hintersteininger M, Erker T, Kloesch B (2015) A8. 20 A novel resveratrol prodrug: anti-proliferative and pro-apoptotic effects in human T-cells. Ann Rheum Dis 74(1):A89–A90. https://doi.org/10.1136/annrheumdis-2015-207259.205

    Article  Google Scholar 

  • Guo W, Li A, Jia Z, Yuan Y, Dai H, Li H (2013) Transferrin modified PEG-PLA-resveratrol conjugates: in vitro and in vivo studies for glioma. Eur J Pharmacol 718(1–3):41–47

    CAS  PubMed  Google Scholar 

  • Hao Q, **ao X, Zhen J, Feng J, Song C, Jiang B, Hu Z (2016) Resveratrol attenuates acute kidney injury by inhibiting death receptor-mediated apoptotic pathways in a cisplatin-induced rat model. Mol Med Rep 14(4):3683–3689

    CAS  PubMed  PubMed Central  Google Scholar 

  • Harde H, Das M, Jain S (2011) Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Exp Opin Drug Deliv 8(11):1407–1424

    CAS  Google Scholar 

  • Holthoff JH, Wang Z, Seely KA, Gokden N, Mayeux PR (2012) Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int 81(4):370–378

    CAS  PubMed  Google Scholar 

  • Hui Y, Lu M, Han Y, Zhou H, Liu W, Li L, ** R (2017) Resveratrol improves mitochondrial function in the remnant kidney from 5/6 nephrectomized rats. Acta Histochem 119(4):392–399

    CAS  PubMed  Google Scholar 

  • Ibrahim A, Al-Hizab FA, Abushouk AI, Abdel-Daim MM (2018) Nephroprotective effects of benzyl isothiocyanate and resveratrol against cisplatin-induced oxidative stress and inflammation. Front Pharmacol. https://doi.org/10.3389/fphar.2018.01268

    Article  PubMed  PubMed Central  Google Scholar 

  • Jafari A, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M (2013) Potential nephroprotective effects of l-carnitine against drug-induced nephropathy: a review of literature. Exp Opin Drug Saf 12(4):523–543

    CAS  Google Scholar 

  • Jang I, Kim E, Lim J, Kim M, Ban T, Yoon H, Choi B (2018) Effects of resveratrol on the renin-angiotensin system in the aging kidney. Nutrients 10(11):1741

    PubMed Central  Google Scholar 

  • Kaloyanides GJ, Pastoriza-Munoz E (1980) Aminoglycoside nephrotoxicity. Kidney Int 18(5):571–582

    CAS  PubMed  Google Scholar 

  • Kane-Gill SL, Goldstein SL (2015) Drug-induced acute kidney injury: a focus on risk assessment for prevention. Crit Care Clin 31(4):675–684

    PubMed  Google Scholar 

  • Kane-Gill SL, Smithburger PL, Kashani K, Kellum JA, Frazee E (2017) Clinical relevance and predictive value of damage biomarkers of drug-induced kidney injury. Drug Saf 40(11):1049–1074

    CAS  PubMed  Google Scholar 

  • Kim DH, Jung YJ, Lee JE, Lee AS, Kang KP, Lee S, Ramkumar KM (2011) SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Ren Physiol 301(2):F427–F435

    CAS  Google Scholar 

  • Kitada M, Koya D (2013) Renal protective effects of resveratrol. Oxid Med Cell Longev. https://doi.org/10.1155/2013/568093

    Article  PubMed  PubMed Central  Google Scholar 

  • Koda-Kimble MA (2012) Koda-Kimble and Young's applied therapeutics: the clinical use of drugs. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  • Kuypers DR, Neumayer HH, Fritsche L, Budde K, Rodicio JL, Vanrenterghem Y, Group LS (2004) Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation 78(8):1204–1211

    CAS  PubMed  Google Scholar 

  • Launay-Vacher V, Rey J-B, Isnard-Bagnis C, Deray G, Daouphars M (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61(6):903–909

    CAS  PubMed  Google Scholar 

  • Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB (2008) Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100(11):773–783

    CAS  PubMed  Google Scholar 

  • Lin C-T, Sun X-Y, Lin A-X (2016) Supplementation with high-dose trans-resveratrol improves ultrafiltration in peritoneal dialysis patients: a prospective, randomized, double-blind study. Ren Fail 38(2):214–221

    CAS  PubMed  Google Scholar 

  • Lin Y-F, Lee Y-H, Hsu Y-H, Chen Y-J, Lin Y-F, Cheng F-Y, Chiu H-W (2017) Resveratrol-loaded nanoparticles conjugated with kidney injury molecule-1 as a drug delivery system for potential use in chronic kidney disease. Nanomedicine 12(22):2741–2756

    CAS  PubMed  Google Scholar 

  • Liu F-C, Tsai H-I, Yu H-P (2015) Organ-protective effects of red wine extract, resveratrol, in oxidative stress-mediated reperfusion injury. Oxid Med Cell Longev. https://doi.org/10.1155/2015/568634

    Article  PubMed  PubMed Central  Google Scholar 

  • Liu S, Zhao M, Zhou Y, Wang C, Yuan Y, Li L, Lu Y (2019) Resveratrol exerts dose-dependent anti-fibrotic or pro-fibrotic effects in kidneys: a potential risk to individuals with impaired kidney function. Phytomedicine 57:223–235

    CAS  PubMed  Google Scholar 

  • Lorenz P, Roychowdhury S, Engelmann M, Wolf G, Horn TF (2003) Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: effect on nitrosative and oxidative stress derived from microglial cells. Nitric Oxide 9(2):64–76

    CAS  PubMed  Google Scholar 

  • Lu Z, Cheng B, Hu Y, Zhang Y, Zou G (2009) Complexation of resveratrol with cyclodextrins: solubility and antioxidant activity. Food Chem 113(1):17–20

    CAS  Google Scholar 

  • Luo C-J, Luo F, Bu Q-D, Jiang W, Zhang W, Liu X-M, Ma R-X (2019) Protective effects of resveratrol on acute kidney injury in rats with sepsis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. https://doi.org/10.5507/bp.2019.006

    Article  PubMed  Google Scholar 

  • Mahmood WA, Mshimesh BAR, Khazaal FAK, Jasim SY, Mahmood AA (2018) Potential effects of resveratrol on obesity-related nephropathy in Iraqi obese women. J Pharm Sci Rev Res 10(5):999–1005

    CAS  Google Scholar 

  • Mattarei A, Azzolini M, Carraro M, Sassi N, Zoratti M, Paradisi C, Biasutto L (2013) Acetal derivatives as prodrugs of resveratrol. Mol Pharm 10(7):2781–2792

    CAS  PubMed  Google Scholar 

  • Mattarei A, Azzolini M, La Spina M, Zoratti M, Paradisi C, Biasutto L (2015) Amino acid carbamates as prodrugs of resveratrol. Sci Rep 5:15216. https://doi.org/10.1038/srep15216

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meng X, Maliakal P, Lu H, Lee M-J, Yang CS (2004) Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agr Food Chem 52(4):935–942

    CAS  Google Scholar 

  • Meng J, Guo F, Xu H, Liang W, Wang C, Yang X-D (2016) Combination therapy using co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells in vivo. Sci Rep 6:22390. https://doi.org/10.1038/srep22390

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins 2(11):2490–2518

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mingeot-Leclercq M-P, Tulkens PM (1999) Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 43(5):1003–1012

    CAS  PubMed  PubMed Central  Google Scholar 

  • Mokni M, Hamlaoui S, Kadri S, Limam F, Amri M, Marzouki L, Aouani E (2016) Grape seed and skin extract protects kidney from doxorubicin-induced oxidative injury. Pak J Pharm Sci 29(3):961–968

    CAS  PubMed  Google Scholar 

  • Montsko G, Nikfardjam MSP, Szabo Z, Boddi K, Lorand T, Ohmacht R, Mark L (2008) Determination of products derived from trans-resveratrol UV photoisomerisation by means of HPLC–APCI-MS. J Photochem Photobiol A Chem 196(1):44–50

    CAS  Google Scholar 

  • Morales AI, Buitrago JM, Santiago JM, Fernández-Tagarro M, López-Novoa JM, Pérez-Barriocanal F (2002) Protective effect of trans-resveratrol on gentamicin-induced nephrotoxicity. Antioxid Redox Signal 4(6):893–898

    CAS  PubMed  Google Scholar 

  • Morales AI, Rodríguez-Barbero A, Vicente-Sánchez C, Mayoral P, López-Novoa JM, Pérez-Barriocanal F (2006) Resveratrol inhibits gentamicin-induced mesangial cell contraction. Life Sci 78(20):2373–2377

    CAS  PubMed  Google Scholar 

  • Moyano-Mendez JR, Fabbrocini G, De Stefano D, Mazzella C, Mayol L, Scognamiglio I, De Rosa G (2014) Enhanced antioxidant effect of trans-resveratrol: potential of binary systems with polyethylene glycol and cyclodextrin. Drug Dev Ind Pharm 40(10):1300–1307

    CAS  PubMed  Google Scholar 

  • Naesens M, Kuypers DR, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481–508

    CAS  PubMed  Google Scholar 

  • Narayanan NK, Nargi D, Randolph C, Narayanan BA (2009) Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 125(1):1–8

    CAS  PubMed  Google Scholar 

  • Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M (2013) A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol 69(5):1057–1073

    CAS  PubMed  Google Scholar 

  • Neves AR, Queiroz JF, Reis S (2016) Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnol 14(1):27

    Google Scholar 

  • Nøhr-Meldgaard K, Ovsepian A, Ingmer H, Vestergaard M (2018) Resveratrol enhances the efficacy of aminoglycosides against Staphylococcus aureus. Int J Antimicrob Agents 52(3):390–396

    PubMed  Google Scholar 

  • Osman A-MM, Telity SA, Damanhouri ZA, Al-Harthy SE, Al-Kreathy HM, Ramadan WS, Kamel F (2015) Chemosensitizing and nephroprotective effect of resveratrol in cisplatin–treated animals. Cancer Cell Int 15(1):6

    PubMed  PubMed Central  Google Scholar 

  • Pannu N, Nadim MK (2008) An overview of drug-induced acute kidney injury. Crit Care Med 36(4):S216–S223. https://doi.org/10.1097/CCM.0b013e318168e375

    Article  CAS  PubMed  Google Scholar 

  • Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K (2011) Clinical trials of resveratrol. Ann N Y Acad Sci 1215(1):161–169

    CAS  PubMed  Google Scholar 

  • Popat R, Plesner T, Davies F, Cook G, Cook M, Elliott P, Cavenagh J (2013) A phase 2 study of SRT 501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol 160(5):714–717

    CAS  PubMed  Google Scholar 

  • Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS (2018) Resveratrol as an anti-cancer agent: A review. Crit Rev Food Sci Nutr 58(9):1428–1447

    PubMed  Google Scholar 

  • Saldanha JF, Leal VO, Rizzetto F, Grimmer GH, Ribeiro-Alves M, Daleprane JB, Mafra D (2016) Effects of resveratrol supplementation in Nrf2 and NF-κB expressions in nondialyzed chronic kidney disease patients: A randomized, double-blind, placebo-controlled, crossover clinical trial. J Ren Nutr 26(6):401–406

    CAS  PubMed  Google Scholar 

  • Şehirli Ö, Şakarcan A, Velioğlu-Öğünç A, Çetinel Ş, Gedik N, Yeğen BÇ, Şener G (2007) Resveratrol improves ifosfamide-induced Fanconi syndrome in rats. Toxicol Appl Pharmacol 222(1):33–41

    PubMed  Google Scholar 

  • Shahbazi F, Sadighi S, Dashti-Khavidaki S, Shahi F, Mirzania M, Abdollahi A, Ghahremani MH (2015) Effect of silymarin administration on cisplatin nephrotoxicity: report from a pilot, randomized, double-blinded, placebo-controlled clinical trial. Phytother Res 29(7):1046–1053

    CAS  PubMed  Google Scholar 

  • Siddalingappa B, Benson HA, Brown DH, Batty KT, Chen Y (2015) Stabilization of resveratrol in blood circulation by conjugation to mPEG and mPEG-PLA polymers: investigation of conjugate linker and polymer composition on stability, metabolism, antioxidant activity and pharmacokinetic profile. PLoS ONE 10(3):e0118824

    PubMed  PubMed Central  Google Scholar 

  • Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265. https://doi.org/10.1038/sj.onc.1206933

    Article  CAS  PubMed  Google Scholar 

  • Silan C, Uzun Ö, Çomunoglu NÜ, Gokçen S, Bedirhan S, Cengiz M (2007) Gentamicin-induced nephrotoxicity in rats ameliorated and healing effects of resveratrol. Biol Pharm Bull 30(1):79–83

    CAS  PubMed  Google Scholar 

  • Singh CK, Ndiaye MA, Ahmad N (2015) Resveratrol and cancer: challenges for clinical translation. Biochim Biophys Acta 1852(6):1178–1185

    CAS  PubMed  Google Scholar 

  • Smoliga JM, Baur JA, Hausenblas HA (2011) Resveratrol and health—a comprehensive review of human clinical trials. Mol Nutr Food Res 55(8):1129–1141

    CAS  PubMed  Google Scholar 

  • Su J-Q, Wen Z, Wen Y-A, **ao W-N, Lin J, Zheng Z-K (2016) Modification and stabilizing effects of PEG on resveratrol-loaded solid lipid nanoparticles. J Iran Chem Soc 13(5):881–890

    CAS  Google Scholar 

  • Summerlin N, Soo E, Thakur S, Qu Z, Jambhrunkar S, Popat A (2015) Resveratrol nanoformulations: challenges and opportunities. Int J Pharm 479(2):282–290

    CAS  PubMed  Google Scholar 

  • Sun L-J, Sun Y-N, Chen S-J, Liu S, Jiang G-R (2017) Resveratrol attenuates skeletal muscle atrophy induced by chronic kidney disease via MuRF1 signaling pathway. Biochem Biophys Res Commun 487(1):83–89

    CAS  PubMed  Google Scholar 

  • Tacar O, Sriamornsak P, Dass CR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 65(2):157–170

    CAS  PubMed  Google Scholar 

  • Tatsioni A, Chung M, Sun Y, Kupelnick B, Lichtenstein AH, Perrone R, Bonis PA (2005) Effects of fish oil supplementation on kidney transplantation: a systematic review and meta-analysis of randomized, controlled trials. J Am Soc Nephrol 16(8):2462–2470

    CAS  PubMed  Google Scholar 

  • Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Aisen PS (2015) A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology 85(16):1383–1391

    CAS  PubMed  PubMed Central  Google Scholar 

  • Valentovic MA, Ball JG, Brown JM, Terneus MV, McQuade E, Van Meter S, Williams T (2014) Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress. Toxicol In Vitro 28(2):248–257

    CAS  PubMed  Google Scholar 

  • Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Lin H-Y (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS ONE 6(6):e19881. https://doi.org/10.1371/journal.pone.0019881

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Varoni EM, Lo Faro AF, Sharifi-Rad J, Iriti M (2016) Anticancer molecular mechanisms of resveratrol. Front Nutr 3:8. https://doi.org/10.3389/fnut.2016.00008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Venkatesan N, Punithavathi D, Arumugam V (2000) Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 129(2):231–234

    CAS  PubMed  PubMed Central  Google Scholar 

  • Vestergaard M, Ingmer H (2019) Antibacterial and antifungal properties of resveratrol. Int J Antimicrob Agents 53(6):716–723

    CAS  PubMed  Google Scholar 

  • Vijayakumar MR, Kumari L, Patel KK, Vuddanda PR, Vajanthri KY, Mahto SK, Singh S (2016) Intravenous administration of trans-resveratrol-loaded TPGS-coated solid lipid nanoparticles for prolonged systemic circulation, passive brain targeting and improved in vitro cytotoxicity against C6 glioma cell lines. RSC Adv 6(55):50336–50348

    CAS  Google Scholar 

  • Walle T (2011) Bioavailability of resveratrol. Ann N Y Acad Sci 1215(1):9–15. https://doi.org/10.1111/j.1749-6632.2010.05842.x

    Article  CAS  PubMed  Google Scholar 

  • Wang Z-Y (2001) Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 48(1):S72–S76

    CAS  PubMed  Google Scholar 

  • Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11(6):694–703

    CAS  PubMed  Google Scholar 

  • Wiederrecht G, Lam E, Hung S, Martin M, Sigal N (1993) The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 696(1):9–19

    CAS  PubMed  Google Scholar 

  • **a N, Strand S, Schlufter F, Siuda D, Reifenberg G, Kleinert H, Li H (2013) Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide 32:29–35

    CAS  PubMed  Google Scholar 

  • **ao Z, Chen C, Meng T, Zhang W, Zhou Q (2016) Resveratrol attenuates renal injury and fibrosis by inhibiting transforming growth factor-β pathway on matrix metalloproteinase 7. Exp Biol Med 241(2):140–146

    CAS  Google Scholar 

  • Xu S, Gao Y, Zhang Q, Wei S, Chen Z, Dai X, Zhao K-S (2016) SIRT1/3 activation by resveratrol attenuates acute kidney injury in a septic rat model. Oxid Med Cell Longev. https://doi.org/10.1155/2016/7296092

    Article  PubMed  PubMed Central  Google Scholar 

  • Xue H-Y, Yuan L, Cao Y-J, Fan Y-P, Chen X-L, Huang X-Z (2016) Resveratrol ameliorates renal injury in spontaneously hypertensive rats by inhibiting renal micro-inflammation. Biosci Rep. https://doi.org/10.1042/BSR20160035

    Article  PubMed  PubMed Central  Google Scholar 

  • Yu M, Xue J, Li Y, Zhang W, Ma D, Liu L, Zhang Z (2013) Resveratrol protects against arsenic trioxide-induced nephrotoxicity by facilitating arsenic metabolism and decreasing oxidative stress. Arch Toxicol 87(6):1025–1035

    CAS  PubMed  Google Scholar 

  • Zhang J, Tian Q, Zhou S-F (2006) Clinical pharmacology of cyclophosphamide and ifosfamide. Curr Drug Ther 1(1):55–84

    CAS  Google Scholar 

  • Zhang W, Liu Y, Ge M, **g J, Chen Y, Jiang H, Zhang Z (2014) Protective effect of resveratrol on arsenic trioxide-induced nephrotoxicity in rats. Nutr Res Pract 8(2):220–226

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu Y, Fu J, Shurlknight KL, Soroka DN, Hu Y, Chen X, Sang S (2015) Novel resveratrol-based aspirin prodrugs: synthesis, metabolism, and anticancer activity. J Med Chem 58(16):6494–6506

    CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, Faculty of Pharmacy, Kermanshah University of Medical Sciences, P.O.Box: 67145-1673, Kermanshah, 6734667149, Iran

    Foroud Shahbazi & Lida Shojaei

  2. Pharmaceutical Sciences Research Center, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Foroud Shahbazi & Lida Shojaei

  3. Department of Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    Fakhrossadat Farvadi

  4. Liver Transplantation Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

    Simin Dashti-Khavidaki

  5. Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran

    Sara Ataei

Authors
  1. Foroud Shahbazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fakhrossadat Farvadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Simin Dashti-Khavidaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sara Ataei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lida Shojaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lida Shojaei.

Ethics declarations

Ethical statement

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

Foroud Shahbazi has no conflict of interest. Fakhrossadat Farvadi has no conflict of interest. Simin Dashti‑Khavidaki has no conflict of interest. Sara Ataei has no conflict of interest. Lida Shojaei has no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shahbazi, F., Farvadi, F., Dashti-Khavidaki, S. et al. Potential nephroprotective effects of resveratrol in drug induced nephrotoxicity: a narrative review of safety and efficacy data. ADV TRADIT MED (ADTM) 20, 529–544 (2020). https://doi.org/10.1007/s13596-020-00432-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13596-020-00432-y

Keywords

Search

Navigation